Frontier Pharma: Versatile Innovation in Oncology - Identifying and Commercializing Versatile First-in-Class Innovation
"Frontier
Pharma: Versatile Innovation in Oncology - Identifying and
Commercializing Versatile First-in-Class Innovation"
The Report covers current Market Trends, Analysis, Forecast, Review,
Share, Size, Growth, Effect.
Description-
The
oncology therapy area comprises a large and diverse range of
indications, encompassing virtually all sites and tissues in the
human body. These indications are the leading cause of death in
economically developed countries and the second-leading cause of
death in developing countries and present a major global health
burden. Across the pharmaceutical industry as a whole, the oncology
pipeline is far larger than any other therapy area, with 6,484
products in active development across all oncology indications, and
2,084 first-in-class products in development across all stages.
Due
to a degree of crossover between oncology indications in terms of
their underlying pathophysiology, it is not uncommon for products
being developed for this therapy area to have developmental programs
testing them across multiple indications. Some 473 first-in-class
pipeline products are in concurrent development for two or more of
the top 20 cancer sites ranked by incidence. The most promising
versatile first-in-class molecular targets predominantly consist of
receptor tyrosine kinases and their downstream signal transduction
kinases, although a number of other cancer-related processes such as
DNA repair, cancer immunosurveillance and apoptotic pathways are also
targeted.
Scope
- With 6,484 products in active development across all oncology indications, this is the largest therapy area pipeline by a considerable margin.
- What factors are driving this high level of R&D activity?
- Which indications have the highest concentration of pipeline products?
- Although the unmet need varies between and within indications, this need is primarily for improved overall survival rates in patients, particularly those at the late stage of the disease.
- Which first-in-class molecular targets appear able to best address the key unmet needs within oncology?
- The variation in molecule type has shifted away from small molecules, the dominance of which has decreased from 94% across marketed products to 49% across the pipeline.
- ….................
Reasons to buy
- Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis, and the treatment options across the key oncology indications
- Acquire a detailed understanding of the 20 most common oncology indications by incidence, pinpointing the unmet needs for each indication
- Assess the market for oncology in terms of the molecular targets that are approved across multiple indications and the predominant molecule types and targets
- Analyze the oncology pipeline and stratify by stage of development, molecule type, molecular target, and first-in-class status
- Understand the level of versatility across the pipeline and within each molecular target. Assess the pipeline activity of each versatile first-in-class product and the indications that they are in development for
…............
Comments
Post a Comment